ArticleJournal of cancer research and clinical oncology2023

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.

Hélène Doubre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.